Exceptional 106-month survival in multiply relapsed small cell lung cancer after sequential anlotinib and short-course sintilimab: a case report
Ruzhu Wang, Yishan Lu, Tianshu Yang, Yuting Zhang, Jingwen Chen, Ping Gao · 2026
Read Exceptional 106-month survival in multiply relapsed small cell lung cancer after sequential anlotinib and short-course sintilimab: a case report by Ruzhu Wang, Yishan Lu, Tianshu Yang, Yuting Zhang, Jingwen Chen, Ping Gao (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13597405.txt.
Description
Ruzhu Wang and co-authors report a woman with small cell lung cancer who lived one hundred six months after diagnosis, far beyond the usual course of this aggressive disease. She was sixty-four, had never smoked, and first responded partly to chemo and radiation in 2017. The cancer returned the next year and kept advancing through two further chemo regimens.
A vessel-blocking drug started in 2019 shrank the tumor. When spread to a neck lymph node was confirmed in 2020, an immune drug was added for a short course. The long control that followed such a sequence is very uncommon after several relapses. The authors discuss how blocking vessels and freeing the immune system may reinforce each other.
Catalog record
| CREATOR | Ruzhu Wang, Yishan Lu, Tianshu Yang, Yuting Zhang, Jingwen Chen, Ping Gao |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 24 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |